BPA CALL
ActiveHT001426FE062
Department of Defense › Defense Health Agency › DEFENSE HEALTH AGENCY
$244.6K
obligated · signed 4 months ago
ACQUISITION OF NEURACEQ (FLORBETABEN F18).
Performance timeline
Start
May 26, 2026
End
May 26, 2027
with all options
Loading status
This contract is likely in the recompete window
Ends with all options: May 26, 2027
SOFIE CO.
Contract HT001426FE062
UEI
JV1AHJHGUGG3
Parent Company
SOFIE CO.
Capabilities & Certifications
Headquarters Location
Congressional District: 10
Current Obligation
$244,574
Base + Exercised Options
$244,574
Total Ceiling Value
$244,574
Contract Type
FIRM FIXED PRICE
NAICS
PHARMACEUTICAL PREPARATION MANUFACTURING
PSC
DRUGS AND BIOLOGICALS
Place of Performance
Congressional District: 08
Awarding Agency
Funding Agency
Contract Vehicle
HT001424A0002
BPADepartment of Defense
Award type: SINGLE AWARD
Solicitation procedures, competition exceptions, labor standards and account totals.